Drug Type Contrast agent, Small molecule drug |
Synonyms PMI 03, PMI03 |
Target- |
Action enhancers |
Mechanism Magnetic resonance imaging enhancers |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Alzheimer Disease | Phase 1 | South Korea | 30 Jan 2022 | |
| Neuroinflammation | Phase 1 | South Korea | 30 Jan 2022 | |
| Parkinson Disease | Phase 1 | South Korea | 30 Jan 2022 | |
| Neurodegenerative Diseases | Phase 1 | United States | 22 Aug 2019 | |
| Inflammation | Phase 1 | United States | 28 Jul 2019 | |
| Nerve Degeneration | Phase 1 | - | - |





